Semaglutide lowers cardiovascular events even without major weight loss, researchers report
Semaglutide’s Expanding Role: Beyond Weight Loss to Comprehensive Cardiometabolic Care Recent findings from the SELECT trial, published in The Lancet, are reshaping the understanding of semaglutide and other GLP-1 receptor agonists (GLP-1RAs). The study demonstrates that the cardiovascular benefits of semaglutide aren’t solely tied to weight loss, suggesting a broader impact on cardiometabolic health. This … Read more